Molekulare Mechanismen von MYC als Stressresistenzfaktor

Cancer is one of the leading causes of death worldwide. The underlying tumorigenesis is driven by the accumulation of alterations in the genome, eventually disabling tumor suppressors and activating proto-oncogenes. The MYC family of proto-oncogenes shows a strong deregulation in the majority of tumor entities. However, the exact mechanisms that contribute to MYC-driven oncogenesis remain largely unknown. Over the past decades, the influence of the MYC protein on transcription became increasingly apparent and was thoroughly investigated. Additionally, in recent years several publications provided evidence for so far unreported functions of MYC that are independent of a mere regulation of target genes. These findings suggest an additional role of MYC in the maintenance of genomic stability and this role is strengthened by key findings presented in this thesis. In the first part, I present data revealing a pathway that allows MYC to couple transcription elongation and DNA double-strand break repair, preventing genomic instability of MYC-driven tumor cells. This pathway is driven by a rapid transfer of the PAF1 complex from MYC onto RNAPII, a process that is mediated by HUWE1. The transfer controls MYC-dependent transcription elongation and, simultaneously, the remodeling of chromatin structure by ubiquitylation of histone H2B. These regions of open chromatin favor not only elongation but also DNA double-strand break repair. In the second part, I analyze the ability of MYC proteins to form multimeric structures in response to perturbation of transcription and replication. The process of multimerization is also referred to as phase transition. The observed multimeric structures are located proximal to stalled replication forks and recruit factors of the DNA-damage response and transcription termination machinery. Further, I identified the HUWE1-dependent ubiquitylation of MYC as an essential step in this phase transition. Cells lacking the ability to form multimers display genomic instability and ultimately undergo apoptosis in response to replication stress. Both mechanisms present MYC as a stress resilience factor under conditions that are characterized by a high level of transcriptional and replicational stress. This increased resilience ensures oncogenic proliferation. Therefore, targeting MYC’s ability to limit genomic instability by uncoupling transcription elongation and DNA repair or disrupting its ability to multimerize presents a therapeutic window in MYC-dependent tumors.Tumorerkrankungen sind eine der häufigsten Todesursachen weltweit. Für die Entstehung und Entwicklung eines Tumors sind Veränderungen im Genom verantwortlich, wobei Proto-Onkogene aktiviert und Tumorsuppressorgene inaktiviert werden. Die MYC-Familie der Proto-Onkogene ist in der Mehrzahl der menschlichen Tumorerkrankungen stark dereguliert. Der genaue Mechanismus, der in MYC-getriebenen Tumoren eine Rolle spielt, ist aber weiterhin ungeklärt. In den letzten Jahrzehnten wurde die Funktion von MYC als Transkriptionsfaktor in den Vordergrund gestellt. Veröffentlichungen der letzten Jahre deuten zusätzlich auf mehrere, bisher unbekannte Funktionen hin, die unabhängig von einer bloßen Regulation von Zielgenen sind und auf eine zusätzliche Rolle bei der Erhaltung der genomischen Stabilität hinweisen. Diese Rolle wird durch wesentliche Ergebnisse dieser Doktorarbeit gestärkt. In dem ersten Teil der Doktorarbeit präsentiere ich einen Pathway, der es MYC ermöglicht, transkriptionelle Elongation und Doppelstrangbruch-Reparatur zu koppeln, wodurch genomische Instabilität in MYC-gesteuerten Tumorzellen limitiert wird. Dieser Pathway wird durch einen schnellen Transfer des PAF1-Komplexes von MYC auf die RNAPII angetrieben, bei dem HUWE1 eine essenzielle Rolle einnimmt. Der Transfer steuert die MYC-abhängige transkriptionelle Elongation und gleichzeitig die Öffnung der Chromatinstruktur. Dies geschieht durch Ubiquitylierung des Histons H2B zugunsten von sowohl transkriptioneller Elongation als auch der DNA-Doppelstrangbruchreparatur. In dem zweiten Teil der Doktorarbeit analysiere ich die Fähigkeit von MYC-Proteinen, als Reaktion auf eine Störung der Transkription und/oder Replikation multimere Strukturen bilden zu können. Diese Fähigkeit wird auch als Phasentrennung bezeichnet. Die multimere Strukturen befinden sich in der Nähe von blockierten Replikationsgabeln und rekrutieren Faktoren der DNA-Schadensreaktion und der Transkriptionsterminationsmaschinerie. Die HUWE1-abhängige Ubiquitylierung von MYC habe ich als wesentlichen Schritt der Phasentrennung identifiziert. Zellen ohne die Fähigkeit zur Bildung von Multimeren zeigen als Reaktion auf Replikationsstress exzessive genomische Instabilität und letztendlich Apoptose auf. Beide Mechanismen machen MYC zu einem Faktor, der genomische Instabilität als Resultat von unphysiologischem Transkriptions- und Replikationsstress limitiert und damit die onkogene Zellteilung gewährleistet. Eine gezielte Beeinflussung der aufgeführten Mechanismen, durch welche MYC die genomische Instabilität limitiert, kann bei MYC-abhängigen Tumoren von großem therapeutischem Nutzen sein

Overexpressed c-Myc Sensitizes Cells to TH1579, a Mitotic Arrest and Oxidative DNA Damage Inducer

Previously, we reported that MTH1 inhibitors TH588 and TH1579 selectively induce oxidative damage and kill Ras-expressing or -transforming cancer cells, as compared to non-transforming immortalized or primary cells. While this explains the impressive anti-cancer properties of the compounds, the molecular mechanism remains elusive. Several oncogenes induce replication stress, resulting in under replicated DNA and replication continuing into mitosis, where TH588 and TH1579 treatment causes toxicity and incorporation of oxidative damage. Hence, we hypothesized that oncogene-induced replication stress explains the cancer selectivity. To test this, we overexpressed c-Myc in human epithelial kidney cells (HA1EB), resulting in increased proliferation, polyploidy and replication stress. TH588 and TH1579 selectively kill c-Myc overexpressing clones, enforcing the cancer cell selective killing of these compounds. Moreover, the toxicity of TH588 and TH1579 in c-Myc overexpressing cells is rescued by transcription, proteasome or CDK1 inhibitors, but not by nucleoside supplementation. We conclude that the molecular toxicological mechanisms of how TH588 and TH1579 kill c-Myc overexpressing cells have several components and involve MTH1-independent proteasomal degradation of c-Myc itself, c-Myc-driven transcription and CDK activation

Nucleolar detention of NONO shields DNA double-strand breaks from aberrant transcripts

RNA-binding proteins emerge as effectors of the DNA damage response (DDR). The multifunctional non-POU domain-containing octamer-binding protein NONO/p54$^{nrb}$ marks nuclear paraspeckles in unperturbed cells, but also undergoes re-localization to the nucleolus upon induction of DNA double-strand breaks (DSBs). However, NONO nucleolar re-localization is poorly understood. Here we show that the topoisomerase II inhibitor etoposide stimulates the production of RNA polymerase II-dependent, DNA damage-inducible antisense intergenic non-coding RNA (asincRNA) in human cancer cells. Such transcripts originate from distinct nucleolar intergenic spacer regions and form DNA–RNA hybrids to tether NONO to the nucleolus in an RNA recognition motif 1 domain-dependent manner. NONO occupancy at protein-coding gene promoters is reduced by etoposide, which attenuates pre-mRNA synthesis, enhances NONO binding to pre-mRNA transcripts and is accompanied by nucleolar detention of a subset of such transcripts. The depletion or mutation of NONO interferes with detention and prolongs DSB signalling. Together, we describe a nucleolar DDR pathway that shields NONO and aberrant transcripts from DSBs to promote DNA repair

Ubiquitylation of MYC couples transcription elongation with double-strand break repair at active promoters

© 2020 Elsevier Inc. The MYC oncoprotein globally affects the function of RNA polymerase II (RNAPII). The ability of MYC to promote transcription elongation depends on its ubiquitylation. Here, we show that MYC and PAF1c (polymerase II-associated factor 1 complex) interact directly and mutually enhance each other's association with active promoters. PAF1c is rapidly transferred from MYC onto RNAPII. This transfer is driven by the HUWE1 ubiquitin ligase and is required for MYC-dependent transcription elongation. MYC and HUWE1 promote histone H2B ubiquitylation, which alters chromatin structure both for transcription elongation and double-strand break repair. Consistently, MYC suppresses double-strand break accumulation in active genes in a strictly PAF1c-dependent manner. Depletion of PAF1c causes transcription-dependent accumulation of double-strand breaks, despite widespread repair-associated DNA synthesis. Our data show that the transfer of PAF1c from MYC onto RNAPII efficiently couples transcription elongation with double-strand break repair to maintain the genomic integrity of MYC-driven tumor cells

Recruitment of BRCA1 limits MYCN-driven accumulation of stalled RNA polymerase

MYC is an oncogenic transcription factor that binds globally to active promoters and promotes transcriptional elongation by RNA polymerase II (RNAPII) 1,2 . Deregulated expression of the paralogous protein MYCN drives the development of neuronal and neuroendocrine tumours and is often associated with a particularly poor prognosis 3 . Here we show that, similar to MYC, activation of MYCN in human neuroblastoma cells induces escape of RNAPII from promoters. If the release of RNAPII from transcriptional pause sites (pause release) fails, MYCN recruits BRCA1 to promoter-proximal regions. Recruitment of BRCA1 prevents MYCN-dependent accumulation of stalled RNAPII and enhances transcriptional activation by MYCN. Mechanistically, BRCA1 stabilizes mRNA decapping complexes and enables MYCN to suppress R-loop formation in promoter-proximal regions. Recruitment of BRCA1 requires the ubiquitin-specific protease USP11, which binds specifically to MYCN when MYCN is dephosphorylated at Thr58. USP11, BRCA1 and MYCN stabilize each other on chromatin, preventing proteasomal turnover of MYCN. Because BRCA1 is highly expressed in neuronal progenitor cells during early development 4 and MYC is less efficient than MYCN in recruiting BRCA1, our findings indicate that a cell-lineage-specific stress response enables MYCN-driven tumours to cope with deregulated RNAPII function

MYCN recruits the nuclear exosome complex to RNA polymerase II to prevent transcription-replication conflicts

The MYCN oncoprotein drives the development of numerous neuroendocrine and pediatric tumors. Here we show that MYCN interacts with the nuclear RNA exosome, a 3'-5' exoribonuclease complex, and recruits the exosome to its target genes. In the absence of the exosome, MYCN-directed elongation by RNA polymerase II (RNAPII) is slow and non-productive on a large group of cell-cycle-regulated genes. During the S phase of MYCN-driven tumor cells, the exosome is required to prevent the accumulation of stalled replication forks and of double-strand breaks close to the transcription start sites. Upon depletion of the exosome, activation of ATM causes recruitment of BRCA1, which stabilizes nuclear mRNA decapping complexes, leading to MYCN-dependent transcription termination. Disruption of mRNA decapping in turn activates ATR, indicating transcription-replication conflicts. We propose that exosome recruitment by MYCN maintains productive transcription elongation during S phase and prevents transcription-replication conflicts to maintain the rapid proliferation of neuroendocrine tumor cells